Cancer Stem Cells (CSCs) have been recently identified and their role in carcinogenesis has been ascertained. CSCs have been correlated with high relapse in certain cancers, multiple drug resistance against chemotherapy and metastasis. Several markers such as CD133, CD24, CD44, EpCAM, and CD26 have been identified to isolate and characterize CSCs. None of these markers or their combinations are universal in nature and can be used to isolate CSCs from all types of cancer. CD90 is one such marker whose expression has been extensively studied in recent years. CD90+ cells have been isolated from several types of tumors and shown to exhibit cardinal properties of CSCs such as proliferation, differentiation, spheroid formation, metastasis and ability to form tumor xenograft in immunodeficient mice. It is also found to be co-expressed with several other CSC markers. CD90 is therefore, suggested as a candidate marker as well as a potential therapeutic target for elimination of CSCs.
ReyaT., MorrisonS.J., ClarkeM.F. and WeissmanI.L., Stem cells, cancer, and cancer stem cells, Nature. 414 (2001), 105-111.
3.
AlisonM.R., IslamS. and WrightN.A., Stem cells in cancer: instigators and propagators, J Cell Sci.123 (2010), 2357-2368.
4.
FriedmanG.K. and GillespieG.Y., Cancer stem cells and pediatric solid tumors, Cancers. 3 (2011), 298-318.
5.
CaldasC., Cancer sequencing unravels clonal evolution, Nat Biotechnol.30 (2012), 408-410.
6.
FuldaS. and PervazeS., Apoptosis signaling in cancer stem cells, Int J Biochem Cell Biol.42 (2010), 31-38.
7.
ClarkeM.F. and BeckerM.W., Stem cells: the real culprits in cancer, Sci Am.295 (2006), 52-59.
8.
ClarkeM.F. and FullerM., Stem cells and cancer: two faces of eve, Cell. 124 (2006), 1111-1115.
9.
GreavesM., Cancer stem cells: back to Darwin, Semin Cancer Biol.20 (2010), 65-70.
10.
JordanC.T., GuzmanM.L. and NobleM., Cancer stem cells, N Engl J Med.355 (2006), 1253-1261.
11.
HuntlyB.J.P. and GillilandD.G., Leukemia stem cells and the evolution of Cancer Stem Cells, Nat Rev Cancer.5 (2005), 311-321.
12.
BonnetD. and DickJ.E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoetic cell, Nat Med.3 (1997), 730-737.
13.
LiS.C., LeeK.L., LuoJ., ZhongJ.F. and LoudonW.G., Convergence of normal stem cell and cancer stem cell developmental stage: Implication for differential therapies, World J Stem Cells.3 (2011), 83-88.
14.
VisvaderJ.E. and LindemanG.J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions, Nat Rev Cancer.8 (2008), 755-768.
15.
SinghS.K., HawkinsC., ClarkeI.D., SquireJ.A., BayaniJ., HideT., CusimanoM.D. and DirksP.B., Identification of human brain tumour initiating cells, Nature. 432 (2004), 396-401.
16.
Ricci-VitianiL., LombardiD.G., PilozziE., BiffoniM., TodaroM., PeschleC. and De MariaR., Identification and expansion of human colon-cancer-initiating cells, Nature. 445 (2007), 111-115.
17.
GhaniF.I., YamazakiH., IwataS., OkamotoT., AoeK., OkabeK., MimurabY., FujimotocN., KishimotocT., YamadadT., XueC.W. and MorimotoaC., Identification of cancer stem cell markers in human malignant mesothelioma cells, Biochem. Biophys. Res. Commun.404 (2011), 735-742.
18.
Al-HajjM., WichaM.S., Benito-HernandezA., MorrisonS.J. and ClarkeM.F., Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci U S A.100 (2003), 3983-3988.
19.
ZhouJ., ZhangH., GuP., BaiJ., MargolickJ.B. and ZhangY., NF-kappa B pathway inhibitors preferentially inhibit breast cancer stem-like cells, Breast Cancer Res Treat.111 (2008), 419-427.
PrinceM.E., SivanandanR., KaczorowskiA., WolfG.T., KaplanM.J., DalerbaP., WeissmanI.L., ClarkeM.F. and AillesL.E., Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma, Proc Natl Acad Sci U S A.104 (2007), 973-978.
22.
GerberJ.M., GucwaJ.L., EsopiD., GurelM., HaffnerM.C., ValaM., NelsonW.G., JonesR.J. and YegnasubramanianS., Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations, Oncotarget. 4 (2013), 715-728.
23.
KisselbachL., MergeM., BossieA. and BoyA., CD90 Expression on human primary cells and elimination of contaminating fibroblasts from cell cultures, Cytotechnology. 59 (2009), 31-44.
24.
YangZ.F., HoD.W., NgM.N., LauC.K., YuW.C., NgaiP., ChuP.W., LamC.T., PoonR.T. and FanS.T., Significance of CD90+ Cancer Stem Cells in Human Liver Cancer, Cancer Cell. 13 (2008), 153-166.
25.
TrueL.D., ZhangH., YeM., HuangC.-Y., NelsonP.S., von HallerP.D., TjoelkerL.W., KimJ.S., QianW.J., SmithR.D., EllisW.J., LiebeskindE.S. and LiuA.Y., CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker, Mod. Pathol.23 (2010), 1346-1356.
26.
ZhuL., ZhangW., WangJ. and LiuR., Evidence of CD90+ CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma, Tumor Biol.36 (2015), 5353-5360.
27.
JiangJ., ZhangY., ChuaiS., WangZ., ZhengD., XuF., ZhangY., LiC., LiangY. and ChenZ., Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype, Oncogene. 31 (2012), 671-682.
28.
KunjithapathamR., KarthikeyanS., GeschwindJ.F., KiesermanE., LinM., FuD.X., KanniappanaS.G. and RussellH., Reversal of Anchorage-Independent Multicellular Spheroid into a Monolayer Mimics a Metastatic Model, Sci Rep.4 (2014), 6816.
29.
TangK.H., DaiY.D., TongM., ChanY.P., KwanP.S., FuL., QinY.R., TsaoS.W., LungH.L., LungM.L., TongD.K., LawS., ChanK.W., MaS. and GuanX.Y., A CD90+ tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer, Cancer Res.73 (2013), 2322-2332.
30.
WangP., GaoQ., SuoZ., MuntheE., SolbergS., MaL., WangM., WesterdaalN.A., KvalheimG. and GaudernackG., Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines, PLoS One. 8 (2013), e57020.
31.
WooS.R., OhY.T., AnJ.Y., KangB.G., NamD.H. and JooK.M., Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness, Anat Cell Biol.48 (2015), 44-53.
32.
HeJ., LiuY., ZhuT., ZhuJ., DiMecoF., VescoviA.L., HethJ.A., MuraszkoK.M., FanX. and LubmanD.M., CD90 is Identified as a Candidate Marker for Cancer Stem Cells in Primary High-Grade Gliomas Using Tissue Microarrays, Mol Cell Proteomics.11 (2012), M111.010744-M111.010744.
33.
YamashitaT., HondaM., NakamotoY., BabaM., NioK., HaraY., ZengS.S., HayashiT., KondoM., TakatoriH., YamashitaT., MizukoshiE., IkedaH., ZenY., TakamuraH., WangX.W. and KanekoS., Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma, Hepatology. 57 (2013), 1484-1497.
34.
OhgaN., IshikawaS., MaishiN., AkiyamaK., HidaY., KawamotoT., SadamotoY., OsawaT., YamamotoK., KondohM., OhmuraH., ShinoharaN., NonomuraK., ShindohM. and HidaK., Heterogeneity of tumor endothelial cells: Comparison between tumor endothelial cells isolated from high- and low-metastatic tumors, Am. J. Pathol.180 (2012), 1294-1307.
35.
ZhuJ., ThakolwiboonS., LiuX., ZhangM. and LubmanD.M., Overexpression of CD90 (Thy-1) in Pancreatic Adenocarcinoma Present in the Tumor Microenvironment, PLoS One. 9 (2014), e115507.
36.
LiuG., YuanX., ZengZ., TuniciP., NgH., AbdulkadirI.R., LuL., IrvinD., BlackK.L. and YuJ.S., Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma, Mol Cancer. 5 (2006), 67.
37.
HoD.W., YangZ.F., YiK., LamC.T., NgM.N.P., YuW.C., LauJ., WanT., WangX., YanZ., LiuH., ZhangY. and FanS.T., Gene expression profiling of liver cancer stem cells by RNA-sequencing, PLoS One. 7 (2102), e37159.
38.
SukowatiC.H.C., AnfusoB., TorreG., FrancalanciP., CrocèL.S. and TiribelliC., The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In-Vivo and In-vitro Study, PLoS One. 8 (2013), e76830.
39.
YanH., DongX., ZhongX., YeJ., ZhouY., YangX., ShenJ. and ZhangJ., Inhibitions of epithelial to mesenchymal transition and cancer stem cells like properties are involved in miR-148a-mediated anti-metastasis of hepatocellular carcinoma, Mol. Carcinog.53 (2014), 960-969.
